MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.310
-0.070 (-5.07%)
Mar 27, 2026, 4:00 PM EDT - Market closed
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,722,782
Market Cap
79.48M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Gossamer Bio | 162 |
| Pelthos Therapeutics | 92 |
| Verrica Pharmaceuticals | 76 |
| PolyPid | 73 |
| Pyxis Oncology | 44 |
| Aardvark Therapeutics | 40 |
| Gain Therapeutics | 25 |
MAIA News
- 2 days ago - Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewsWire
- 24 days ago - MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock - GlobeNewsWire
- 26 days ago - MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market - GlobeNewsWire
- 2 months ago - MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum - GlobeNewsWire
- 3 months ago - MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings - GlobeNewsWire
- 3 months ago - MAIA Biotechnology Announces $1.51 Million Private Placement - GlobeNewsWire
- 3 months ago - MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates - GlobeNewsWire